KORU Medical Systems (NASDAQ:KRMD) COO Christopher Pazdan Buys 5,000 Shares

KORU Medical Systems, Inc. (NASDAQ:KRMD) COO Christopher Pazdan purchased 5,000 shares of the firm’s stock in a transaction on Thursday, May 14th. The stock was acquired at an average price of $3.88 per share, with a total value of $19,400.00. Following the completion of the purchase, the chief operating officer owned 305,131 shares of the company’s stock, valued at $1,183,908.28. The trade was a 1.67% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

KORU Medical Systems Price Performance

KORU Medical Systems stock traded down $0.07 during midday trading on Monday, reaching $3.83. The company’s stock had a trading volume of 108,361 shares, compared to its average volume of 174,595. KORU Medical Systems, Inc. has a 52-week low of $2.63 and a 52-week high of $6.61. The stock has a market capitalization of $175.91 million, a P/E ratio of -76.60 and a beta of 0.43. The stock’s 50-day simple moving average is $4.23 and its 200-day simple moving average is $4.84.

KORU Medical Systems (NASDAQ:KRMD) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.02). KORU Medical Systems had a negative return on equity of 13.61% and a negative net margin of 5.27%.The firm had revenue of $11.76 million during the quarter, compared to analysts’ expectations of $11.28 million. As a group, equities research analysts expect that KORU Medical Systems, Inc. will post -0.03 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on KRMD shares. Weiss Ratings restated a “sell (d-)” rating on shares of KORU Medical Systems in a research note on Tuesday, April 21st. Canaccord Genuity Group restated a “buy” rating and issued a $6.00 price objective on shares of KORU Medical Systems in a research note on Friday, March 13th. B. Riley Financial raised their price objective on KORU Medical Systems from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Finally, Wall Street Zen cut KORU Medical Systems from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.25.

Institutional Trading of KORU Medical Systems

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. First Light Asset Management LLC grew its holdings in KORU Medical Systems by 5.1% during the second quarter. First Light Asset Management LLC now owns 4,681,626 shares of the company’s stock worth $16,760,000 after acquiring an additional 226,700 shares during the period. Topline Capital Management LLC grew its holdings in KORU Medical Systems by 1.1% during the third quarter. Topline Capital Management LLC now owns 3,648,240 shares of the company’s stock worth $13,973,000 after acquiring an additional 39,893 shares during the period. Vanguard Group Inc. grew its holdings in KORU Medical Systems by 2.9% during the third quarter. Vanguard Group Inc. now owns 2,145,772 shares of the company’s stock worth $8,218,000 after acquiring an additional 60,109 shares during the period. Geode Capital Management LLC grew its holdings in KORU Medical Systems by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 1,022,860 shares of the company’s stock worth $5,944,000 after acquiring an additional 16,062 shares during the period. Finally, Acuitas Investments LLC grew its holdings in KORU Medical Systems by 89.6% during the third quarter. Acuitas Investments LLC now owns 763,088 shares of the company’s stock worth $2,923,000 after acquiring an additional 360,594 shares during the period. 58.60% of the stock is owned by institutional investors and hedge funds.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.